{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:47:36Z","timestamp":1761630456364},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11938-005-0017-9","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T14:42:27Z","timestamp":1180881747000},"page":"249-258","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of gastrointestinal acute graft-versus-host disease"],"prefix":"10.1007","volume":"8","author":[{"given":"William A.","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"17_CR1","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/archinte.162.14.1558","volume":"162","author":"IA Tabbara","year":"2002","unstructured":"Tabbara IA, Zimmerman K, Morgan C, Nahleh Z: Allogenic hematopoietic stem cell transplantation. Arch Int Med 2002, 162: 1558\u20131566.","journal-title":"Arch Int Med"},{"key":"17_CR2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V80.7.1838.1838","volume":"80","author":"RA Nash","year":"1992","unstructured":"Nash RA, Pepe MS, Storb R, et al.: Acute graft-versus-host disease: analysis of risk factors after allogenic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992, 80: 1838\u20131845.","journal-title":"Blood"},{"key":"17_CR3","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.V94.4.1465","volume":"94","author":"D Przepiorka","year":"1999","unstructured":"Przepiorka D, Smith TL, Folloder J, et al.: Risk factors for acute graft-versus-host disease after allogenic blood stem cell transplantation. Blood 1999, 94: 1465\u20131470.","journal-title":"Blood"},{"key":"17_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.med.54.101601.152339","volume":"54","author":"GB Vogelsang","year":"2003","unstructured":"Vogelsang GB, Lee L, Bensen-Kennedy DM: Pathogenesis and treatment of graft-versus-host disease after bone marrow transplantation. Ann Rev Med 2003, 54: 29\u201352. A comprehensive review with a focus on pathogenesis.","journal-title":"Ann Rev Med"},{"key":"17_CR5","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cncr.20613","volume":"101","author":"D Couriel","year":"2004","unstructured":"Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004, 101: 1936\u20131946. General overview of acute GVHD.","journal-title":"Cancer"},{"key":"17_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/bbmt.2003.49999","volume":"9","author":"G Akpek","year":"2003","unstructured":"Akpek G, Chinratanalab W, Lee LA, et al.: Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transpl 2003, 9: 46\u201351.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.bmt.1703111","volume":"28","author":"V Ratanatharathorn","year":"2001","unstructured":"Ratanatharathorn V, Ayash L, Lazarus HM, et al.: Chronic graft-versus-host disease: clinical manifestations and therapy. Bone Marrow Transpl 2001, 28: 121\u2013129.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2141.2004.04945.x","volume":"125","author":"MA Higman","year":"2004","unstructured":"Higman MA, Vogelsang GB: Chronic graft-versus-host disease. Br J Haematol 2004, 125: 435\u2013454.","journal-title":"Br J Haematol"},{"key":"17_CR9","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1200\/JCO.2001.19.16.3685","volume":"19","author":"C Cutler","year":"2001","unstructured":"Cutler C, Giri S, Jeyapalan S, et al.: Acute and chronic graft-versus-host disease after allogenic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19: 3685\u20133691.","journal-title":"J Clin Oncol"},{"key":"17_CR10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2001-12-0304","volume":"100","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Beksac M, Hasenclever D, et al.: Transplantation of mobilized peripheral blood cells to HLAidentical siblings with standard risk leukemia. Blood 2002, 100: 761\u2013767.","journal-title":"Blood"},{"key":"17_CR11","first-page":"3702","volume":"95","author":"RE Champlin","year":"2000","unstructured":"Champlin RE, Schmitz N, Horowitz MM, et al.: Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogenic transplantation. Blood 2000, 95: 3702\u20133709.","journal-title":"Blood"},{"key":"17_CR12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.thj.6200399","volume":"5","author":"A Bacigalupo","year":"2004","unstructured":"Bacigalupo A, Palandri F: Management of acute graft versus host disease. Hematol J 2004, 5: 189\u2013196.","journal-title":"Hematol J"},{"key":"17_CR13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbmt.2003.10.006","volume":"10","author":"DR Couriel","year":"2004","unstructured":"Couriel DR, Saliba RM, Giralt S, et al.: Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogenic hematopoietic transplantation. Biol Blood Marrow Transpl 2004, 10: 178\u2013185.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bbmt.2003.12.304","volume":"10","author":"PJ Martin","year":"2004","unstructured":"Martin PJ, McDonald GB, Sanders JE, et al.: Increasingly frequent diagnosis of acute gastrointestinal graftversus-host disease after allogenic hematopoietic cell transplantation. Biol Blood Marrow Transpl 2004, 10: 320\u2013327.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR15","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759","volume":"95","author":"GR Hill","year":"2000","unstructured":"Hill GR, Ferrara JLM: The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogenic bone marrow transplantation. Blood 2000, 95: 2754\u20132759.","journal-title":"Blood"},{"key":"17_CR16","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al.: Consensus conference on acute GVHD grading. Bone Marrow Transpl 1995, 15: 825\u2013828.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V86.2.813.bloodjournal862813","volume":"86","author":"A Gratwohl","year":"1995","unstructured":"Gratwohl A, Hermans J, Apperley J, et al.: Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 1995, 86: 813\u2013818.","journal-title":"Blood"},{"key":"17_CR18","first-page":"1044","volume":"88","author":"K LeBlanc","year":"2003","unstructured":"LeBlanc K, Ringden O, Remberger M: A low body mass index is correlated with poor survival after allogenic stem cell transplantation. Haematologica 2003, 88: 1044\u20131052.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"17_CR19","first-page":"A696","volume":"94","author":"J Doherty","year":"1999","unstructured":"Doherty J, Zahurak M, Margolis J, et al.: Chronic graft-versus-host disease and severe weight loss. Blood 1999, 94[Suppl 1]:A696.","journal-title":"Blood"},{"key":"17_CR20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1703352","volume":"29","author":"DA Jacobsohn","year":"2002","unstructured":"Jacobsohn DA, Margolis J, Doherty J, et al.: Weight loss and malnutrition in patients with chronic graft-versushost disease. Bone Marrow Transpl 2002, 29: 231\u2013236.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR21","first-page":"2062","volume":"9","author":"RA Nash","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, et al.: Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 9: 2062\u20132068.","journal-title":"Blood"},{"key":"17_CR22","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","volume":"76","author":"PJ Martin","year":"1990","unstructured":"Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76: 1464\u20131472.","journal-title":"Blood"},{"key":"17_CR23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00007890-199408270-00008","volume":"58","author":"JM Hings","year":"1994","unstructured":"Hings JM, Severson R, Filipovich AH, et al.: Treatment of moderate and severe acute graft-versus-host disease after allogenic bone marrow transplantation. Transplant 1994, 58: 437\u2013442.","journal-title":"Transplant"},{"key":"17_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","volume":"8","author":"ML MacMillan","year":"2002","unstructured":"MacMillan ML, Weisdorf DJ, Wagner JE, et al.: Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transpl 2002, 8: 387\u2013394.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0016-5085(98)70361-0","volume":"115","author":"GB McDonald","year":"1998","unstructured":"McDonald GB, Bouvier M, Hockenbery DM, et al.: Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastro 1998, 115: 28\u201335.","journal-title":"Gastro"},{"key":"17_CR26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.bmt.1702055","volume":"24","author":"H Bertz","year":"1999","unstructured":"Bertz H, Afting M, Kreisel W, et al.: Feasibility and response to busdesonide as topical corticosteroid therapy for acute intestinal graft-versus-host disease. Bone Marrow Transpl 1999, 24: 1185\u20131189.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bmt.1703269","volume":"28","author":"B Hsu","year":"2001","unstructured":"Hsu B, May R, Carrum G, et al.: Use of anti-thymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transpl 2001, 28: 945\u2013950.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR28","first-page":"973","volume":"87","author":"F Graziani","year":"2002","unstructured":"Graziani F, Van Lint MT, Dominietto A, et al.: Treatment of acute graft-versus-host disease with low-dose, alternate day antithymocyte globulin. Haematologica 2002, 87: 973\u2013978.","journal-title":"Haematologica"},{"key":"17_CR29","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood.V77.8.1821.1821","volume":"77","author":"PJ Martin","year":"1991","unstructured":"Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatments. Blood 1991, 77: 1821\u20131828.","journal-title":"Blood"},{"key":"17_CR30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2004.07.007","volume":"10","author":"JH Antin","year":"2004","unstructured":"Antin JH, Chen AR, Couriel DR, et al.: Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transpl 2004, 10: 655\u2013668. Recent review of various therapies for steroid-refractory disease.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/bbmt.2002.v8.pm11858189","volume":"8","author":"ML MacMillan","year":"2002","unstructured":"MacMillan ML, Weisdorf DJ, Davies SM, et al.: Early anti-thymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transpl 2002, 8: 40\u201346.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/bbmt.2002.v8.pm11939605","volume":"8","author":"S Arai","year":"2002","unstructured":"Arai S, Margolis J, Zahurak M, et al.: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transpl 2002, 8: 155\u2013160.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1399-0012.2001.150301.x","volume":"15","author":"M Remberger","year":"2001","unstructured":"Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O: Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transpl 2001, 15: 147\u201353.","journal-title":"Clin Transpl"},{"key":"17_CR34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bmt.1703032","volume":"27","author":"H Khoury","year":"2001","unstructured":"Khoury H, Kashyap A, Adkins DR, et al.: Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transpl 2001, 27: 1059\u20131064.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14728214.8.2.323","volume":"8","author":"DA Jacobsohn","year":"2003","unstructured":"Jacobsohn DA: Emerging therapies for graft-versus-host disease. Expert Opin Emerging Drugs 2003, 8: 323\u2013338. Recent review of new agents including false hopes","journal-title":"Expert Opin Emerging Drugs"},{"key":"17_CR36","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/00007890-200112270-00010","volume":"72","author":"AI Benito","year":"2001","unstructured":"Benito AI, Furlong T, Martin PJ, et al.: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transpl 2001, 72: 1924\u20131928.","journal-title":"Transpl"},{"key":"17_CR37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1083-8791(03)80016-2","volume":"9","author":"DR Couriel","year":"2003","unstructured":"Couriel DR, Hicks K, Saliba R, et al.: Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transpl 2003, 9: 67\u201368.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"Suppl 1","key":"17_CR38","first-page":"346a","volume":"104","author":"C Cutler","year":"2004","unstructured":"Cutler C, Li S, Kim HT, et al.: Sirolimus and tacrolimus as graft-vs.-host disease prophylaxis in allogenic stem cell transplantation: the Dana-Farber Cancer Institute experience. Blood 2004, 104[Suppl 1]:346a.","journal-title":"Blood"},{"key":"17_CR39","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2004-01-0028","volume":"104","author":"VT Ho","year":"2004","unstructured":"Ho VT, Zahrieh D, Hochberg E, et al.: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation. Blood 2004, 104: 1224\u20131226.","journal-title":"Blood"},{"key":"17_CR40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2141.2004.04856.x","volume":"124","author":"R Srinivasan","year":"2004","unstructured":"Srinivasan R, Chakrabarti S, Walsh T, et al.: Improved survival in steroid-refractory acute graft-versus-host disease after non-myeloablative allogenic transplantation using daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124: 777\u2013786.","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"17_CR41","first-page":"349a","volume":"104","author":"M Weisser","year":"2004","unstructured":"Weisser M, Goede V, Schiel X, Kolb HJ: Steroid refractory GVHD of the gut can be treated effectively with daclizumab and sirolimus. Blood 2004, 104[Suppl 1]:349a.","journal-title":"Blood"},{"key":"17_CR42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2003-12-4241","volume":"104","author":"DR Couriel","year":"2004","unstructured":"Couriel DR, Saliba R, Hicks K, et al.: Tumor necrosis factor alpha blockade for the treatment of steroidrefractory acute GVHD. Blood 2004, 104: 649\u2013654.","journal-title":"Blood"},{"key":"17_CR43","first-page":"1352","volume":"89","author":"F Patriarca","year":"2004","unstructured":"Patriarca F, Sperotto A, Damiani D, et al.: Infliximab treatment for steroid-refractory acute graft-versushost disease. Haematologica 2004, 89: 1352\u20131359.","journal-title":"Haematologica"},{"key":"17_CR44","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2003-01-0267","volume":"102","author":"FM Marty","year":"2003","unstructured":"Marty FM, Lee SJ, Fahey MM, et al.: Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogenic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102: 2768\u20132776.","journal-title":"Blood"},{"key":"17_CR45","unstructured":"Everitt DE: Important drug warning. http:\/www.fda.gov\/medwatch\/SAFETY\/2004\/ remicade_DHCP_dec04.pdf. Accessed January 15, 2005."},{"key":"17_CR46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V95.1.83","volume":"95","author":"D Prezepiorka","year":"2000","unstructured":"Prezepiorka D, Kernan NA, Ippoliti C, et al.: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graftversus-host disease. Blood 2000, 95: 83\u201389.","journal-title":"Blood"},{"key":"17_CR47","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1046\/j.1365-2141.2001.02582.x","volume":"112","author":"W Willenbacher","year":"2001","unstructured":"Willenbacher W, Basara N, Blau IW, et al.: Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001, 112: 820\u2013823.","journal-title":"Br J Haematol"},{"key":"17_CR48","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2004-03-0854","volume":"104","author":"SJ Lee","year":"2004","unstructured":"Lee SJ, Zahrich D, Agura E, et al.: Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104: 1559\u20131564.","journal-title":"Blood"},{"key":"17_CR49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bmt.1703633","volume":"30","author":"M Baudard","year":"2002","unstructured":"Baudard M, Vincent A, Moreau P, et al.: Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM and PSC transplant patients. Bone Marrow Transpl 2002, 30: 287\u2013295.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR50","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/S0041-1345(01)01968-6","volume":"33","author":"N Basara","year":"2001","unstructured":"Basara N, Kiehl MG, Blau W, et al.: Mycophenolate mofetil in the treatment of acute and chronic graft-versus-host disease in hematopoietic stem cell transplant patients: four years of experience. Transpl Proc 2001, 33: 2121\u20132123.","journal-title":"Transpl Proc"},{"key":"17_CR51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-0609.2004.00247.x","volume":"73","author":"JG Kim","year":"2004","unstructured":"Kim JG, Sohn SK, Kim DH, et al.: Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogenic stem cell transplant. Eur J Haematol 2004, 73: 56\u201361.","journal-title":"Eur J Haematol"},{"key":"17_CR52","doi-asserted-by":"crossref","unstructured":"Barrett AJ, Rezvani K, Solomon S, et al.: New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program) 2003, 350\u2013371.","DOI":"10.1182\/asheducation-2003.1.350"},{"key":"17_CR53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biocel.2003.11.001","volume":"36","author":"FP Barry","year":"2004","unstructured":"Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004, 36: 568\u2013584. Good introduction to mesenchymal stem cell clinical uses.","journal-title":"Int J Biochem Cell Biol"},{"key":"17_CR54","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K LeBlanc","year":"2004","unstructured":"LeBlanc K, Rasmussen I, Sundberg B, et al.: Treatment of severe graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363: 1439\u20131441.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"17_CR55","first-page":"S2","volume":"29","author":"F Frassoni","year":"2002","unstructured":"Frassoni F, Labopin M, Bacigalupo A, et al.: Expanded mesenchymal stem cell (MSC) re-infused with HLA identical HSC transplants reduce acute and chronic graft-versus-host disease: a matched pair analysis. Bone Marrow Transpl 2002, 29[Suppl 1]:S2.","journal-title":"Bone Marrow Transpl"},{"key":"17_CR56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/bbmt.2002.v8.pm12014809","volume":"8","author":"T Furlong","year":"2002","unstructured":"Furlong T, Leisenring W, Storb R, et al.: Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transpl 2002, 8: 206\u2013212.","journal-title":"Biol Blood Marrow Transpl"},{"key":"17_CR57","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood.V96.7.2426","volume":"96","author":"HT Grenix","year":"2000","unstructured":"Grenix HT, Volc-Platzer B, Kaths P, et al.: Extracorporeal photochemotherapy in the treatment of steroidrefractory acute graft-versus-host disease: a pilot study. Blood 2000, 96: 2426\u2013431.","journal-title":"Blood"},{"key":"17_CR58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/01.TP.0000128835.06220.44","volume":"78","author":"S Lee","year":"2004","unstructured":"Lee S, Dorken B, Schmitt D: Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T cell senescence in vivo. Transpl 2004, 78: 484\u2013485.","journal-title":"Transpl"},{"key":"17_CR59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1365-2141.2003.04401.x","volume":"122","author":"C Messina","year":"2003","unstructured":"Messina C, Locateli F, Lanino E, et al.: Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122: 118\u2013127.","journal-title":"Br J Haematol"},{"key":"17_CR60","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood-2002-01-0068","volume":"100","author":"G Gorgun","year":"2002","unstructured":"Gorgun G, Miller KB, Foss FM: Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100: 941\u2013947.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0017-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-005-0017-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0017-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T17:44:27Z","timestamp":1587577467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-005-0017-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["17"],"URL":"https:\/\/doi.org\/10.1007\/s11938-005-0017-9","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}